A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

Stopped Due to the adjustment of the R\&D strategy, Suzhou Junjing Biosciences Co., Ltd. decided to terminate this study in September 2023

Conditions

• Locally Advanced or Metastatic NSCLC

Interventions

• DRUG: WJ13404 tablets

Sponsor

Suzhou Junjing BioSciences Co., Ltd.

Collaborators

• [object Object]